18 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
and elicited tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
in tumor-specific in situ production of oncolytic virions, broad immune cell recruitment and tumor destruction. Efficacy was observed across multiple
10-K
2020 FY
ONCR
Oncorus, Inc.
10 Mar 21
Annual report
4:12pm
before infecting nearby tumor cells while stimulating immune cell recruitment and activity.
Using our Synthetic Platform, we have established preclinical … tumors. The inclusion of CCL4 in ONCR-177 may therefore enhance the recruitment of T cells and dendritic cells within a cold tumor to enhance response
424B4
ONCR
Oncorus, Inc.
2 Oct 20
Prospectus supplement with pricing info
12:00am
recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may harm our … -benefit perspective. The therapeutic-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the trial
DRS/A
bndb22w
26 Aug 20
Draft registration statement (amended)
12:00am
S-1
7lp9ava2m5mmkfcuvsor
11 Sep 20
IPO registration
4:49pm
424B4
ymasydpix tzilryqbjp
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
0jby2e7myytfcl
28 Jan 21
Draft registration statement
12:00am
DRS/A
b788p
29 Jul 20
Draft registration statement (amended)
12:00am
DRS/A
5va o8wd3n
20 Dec 19
Draft registration statement (amended)
12:00am
DRS
8wo0 dy00om18
31 Oct 19
Draft registration statement
12:00am
10-Q
vu4nwrpcmf 8nikh
12 Nov 20
Quarterly report
8:01am
- Prev
- 1
- Next